Publication of the 2020 Annual Financial Report
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Onxeo will publish its annual results on April 21, 2021
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
2020 – Full-year report on the liquidity contract
2020 Full-year report on the liquidity contract
Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]
Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen
Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo has received approval for the delisting from Nasdaq Main Market Copenhagen and the concurrent admission to trading on Nasdaq First North Growth Market Denmark
Last day of trading on Nasdaq Copenhagen will be 11 December 2020 and the first day of trading on Nasdaq […]
Half-year 2020 : Management presentation
Watch the replay of the video conference of Judith Greciet, CEO, and Nicolas Fellmann, CFO, commenting on the half-yearly […]
Onxeo reports its financial results for the first half of 2020 and provides an update on its activities
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]
Combined General Meeting of May 29, 2020 in Camera
Shareholders’ Combined General Meeting of May 29, 2020 in Camera Access the Managment Presentation to the General Meeting of […]
Extraordinary General Meeting in camera on 2nd call
Extraordinary General Meeting of 19 June 2020 in camera on 2nd call The Extraordinary General Meeting was held on second […]
Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Onxeo offre 10,7% de son capital à Invus – Biotech Finances
(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]
BFM Business Intégrale Bourse : Onxeo, Company of the Day
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions
The Extraordinary General Meeting will be held on June 19, 2020 on the second call Paris (France), May 29, […]
Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation
Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Publication of the 2019 Universal Registration Document
Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update
Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]
Management Call – FY 19 and perspectives
Download management presentation
Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC
This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology $6.6m […]
Onxeo Will Publish Its Annual Results on April 17, 2020
The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]
Onxeo Publishes Shareholder Newsletter
Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
2019 Full year report on the liquidity contract
Dowload the press release
Onxeo Announces its Financial Agenda for 2020
Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]
Onxeo Enters into Settlement Agreement with SpePharm and SpeBio
Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
Publication of 2017 Registration Document
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference
Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]
Combined General Meeting on May 16, 2018
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update
Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]
Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference
January 9-12, 2017 in San Francisco, CA In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]
Passing on Onxeo’s Extraordinary and Ordinary General Meeting
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Onxeo First Quarter 2016 Financial Information and Business Update
Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]
Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Publication of Shareholder Letter
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]
Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update
Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]
Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Consolidated turnover for 2010
Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and […]
The structure of BioAlliance Pharma’s turnover for Q3 2010 reflects the dynamism of the company’s American and European collaborations
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today […]
Onxeo launches a capital increase by means of an accelerated book-build offering
Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]
Onxeo successfully raises €15 Million with US and European investors
Offering upsized in response to investor demand Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]
Onxeo Reports First-Half 2017 Results and Business Update
Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]
Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma
Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]
Onxeo Grants Exclusive Worldwide License of Validive® developed for the treatment of oral severe mucositis to Monopar Therapeutics
Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive […]
Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm
Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Financial Agenda 2018
Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. […]
Onxeo to attend Key Investor and Partnering Conferences in H1 2018
Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Full-year financial results for 2010
The company posts a profit as a result of an exceptional revenue High potential for further growth Paris, March 3, […]
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]